Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Key Terms
lupus nephritis medical
autoimmune diseases medical
Financial Results
-
Total Revenue: For the three months ended March 31, 2026, total revenue was
$77.7 million 24% from$62.5 million -
Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were
$73.6 million 23% from$60.0 million -
License, Collaboration and Royalty Revenue: For the three months ended March 31, 2026, license, collaboration and royalty revenue from Aurinia’s collaboration partner, Otsuka, was
$4.1 million 64% from$2.5 million
-
Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were
-
Net Income: For the three months ended March 31, 2026, net income was
$34.4 million 48% from$23.3 million -
Diluted Earnings per Share: For the three months ended March 31, 2026, diluted earnings per share was
$0.25 56% from$0.16 -
Cash Flows from Operating Activities: For the three months ended March 31, 2026, cash flows from operating activities were
$32.6 million 2408% from$1.3 million
Cash Position
As of March 31, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of
2026 Total Revenue and Net Product Sales Guidance
Aurinia reiterates its guidance for 2026 total revenue of
“Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases,” stated Kevin Tang, Chief Executive Officer. “LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, now in clinical development for three potential indications, has therapeutic potential across a wide range of autoimmune disorders.”
About Aurinia
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Forward-Looking Statements
This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(in thousands) |
||||||||
|
March 31, 2026 |
December 31, 2025 |
||||||
|
(Unaudited) |
|
||||||
ASSETS |
|
|
||||||
Current assets: |
|
|
||||||
Cash, cash equivalents and restricted cash |
$ |
41,008 |
|
$ |
80,213 |
|
||
Short-term investments |
|
337,775 |
|
|
317,784 |
|
||
Accounts receivable, net |
|
49,175 |
|
|
41,454 |
|
||
Inventory |
|
46,410 |
|
|
45,690 |
|
||
Prepaid expenses and deposits |
|
4,119 |
|
|
5,746 |
|
||
Other current assets |
|
1,757 |
|
|
1,080 |
|
||
Total current assets |
|
480,244 |
|
|
491,967 |
|
||
Deferred tax assets, net |
|
166,917 |
|
|
176,194 |
|
||
Finance right-of-use lease assets |
|
69,508 |
|
|
73,865 |
|
||
Intangible assets, net |
|
3,590 |
|
|
3,761 |
|
||
Operating right-of-use lease assets |
|
1,659 |
|
|
3,596 |
|
||
Property and equipment, net |
|
1,986 |
|
|
2,111 |
|
||
Other noncurrent assets |
|
93 |
|
|
93 |
|
||
Total assets |
$ |
723,997 |
|
$ |
751,587 |
|
||
|
|
|
||||||
LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
||||||
Current liabilities: |
|
|
||||||
Accounts payable |
$ |
2,661 |
|
$ |
3,313 |
|
||
Accrued expenses |
|
58,196 |
|
|
66,621 |
|
||
Finance lease liabilities, current portion |
|
16,519 |
|
|
16,523 |
|
||
Deferred revenue |
|
5,036 |
|
|
3,720 |
|
||
Operating lease liabilities, current portion |
|
1,622 |
|
|
1,067 |
|
||
Other current liabilities |
|
2,522 |
|
|
2,480 |
|
||
Total current liabilities |
|
86,556 |
|
|
93,724 |
|
||
Finance lease liabilities, less current portion |
|
48,181 |
|
|
52,322 |
|
||
Deferred revenue, less current portion |
|
12,413 |
|
|
12,648 |
|
||
Deferred compensation and other noncurrent liabilities |
|
6,903 |
|
|
6,662 |
|
||
Operating lease liabilities, less current portion |
|
2,318 |
|
|
4,900 |
|
||
Total liabilities |
|
156,371 |
|
|
170,256 |
|
||
Shareholders' equity |
|
|
||||||
Common shares — no par value, unlimited shares authorized, 130,771 and 132,323 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively |
|
1,086,650 |
|
|
1,120,035 |
|
||
Additional paid-in capital |
|
96,869 |
|
|
111,263 |
|
||
Accumulated other comprehensive loss |
|
(880 |
) |
|
(599 |
) |
||
Accumulated deficit |
|
(615,013 |
) |
|
(649,368 |
) |
||
Total shareholders' equity |
|
567,626 |
|
|
581,331 |
|
||
Total liabilities and shareholders' equity |
$ |
723,997 |
|
$ |
751,587 |
|
||
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||
(Unaudited) |
||||||||
(in thousands, except per share data) |
||||||||
Three Months Ended |
||||||||
March 31, |
||||||||
|
2026 |
2025 |
||||||
Revenue |
|
|
||||||
Net product sales |
$ |
73,563 |
|
$ |
59,971 |
|
||
License, collaboration and royalty revenue |
|
4,142 |
|
|
2,494 |
|
||
Total revenue |
|
77,705 |
|
|
62,465 |
|
||
Operating expenses |
|
|
||||||
Cost of revenue |
|
6,505 |
|
|
8,574 |
|
||
Selling, general and administrative |
|
22,029 |
|
|
20,339 |
|
||
Research and development |
|
7,470 |
|
|
5,743 |
|
||
Restructuring |
|
— |
|
|
1,533 |
|
||
Other expense, net |
|
279 |
|
|
4,429 |
|
||
Total operating expenses |
|
36,283 |
|
|
40,618 |
|
||
Income from operations |
|
41,422 |
|
|
21,847 |
|
||
Interest income |
|
3,515 |
|
|
3,569 |
|
||
Interest expense |
|
(1,012 |
) |
|
(1,067 |
) |
||
Net income before income taxes |
|
43,925 |
|
|
24,349 |
|
||
Income tax expense |
|
9,570 |
|
|
1,005 |
|
||
Net income |
$ |
34,355 |
|
$ |
23,344 |
|
||
|
|
|
||||||
Earnings per share |
|
|
||||||
Basic |
$ |
0.26 |
|
$ |
0.17 |
|
||
Diluted |
$ |
0.25 |
|
$ |
0.16 |
|
||
|
|
|
||||||
Shares used in computing earnings per share |
|
|
||||||
Basic |
|
132,375 |
|
|
138,917 |
|
||
Diluted |
|
137,639 |
|
|
143,199 |
|
||
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARY |
||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
(Unaudited) |
||||||||
(in thousands) |
||||||||
Three Months Ended March 31, |
||||||||
|
2026 |
2025 |
||||||
Cash flows from operating activities: |
|
|
||||||
Net income |
$ |
34,355 |
|
$ |
23,344 |
|
||
Adjustments to reconcile net income to cash flows from operating activities: |
|
|
||||||
Deferred income tax |
|
9,277 |
|
|
— |
|
||
Share-based compensation |
|
(866 |
) |
|
(3,409 |
) |
||
Amortization and depreciation |
|
4,816 |
|
|
4,856 |
|
||
Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability |
|
(416 |
) |
|
1,812 |
|
||
Net amortization of premiums and discounts on investments |
|
(2,319 |
) |
|
(2,656 |
) |
||
Other, net |
|
581 |
|
|
2,325 |
|
||
Net changes in operating assets and liabilities: |
|
|
||||||
Accounts receivable, net |
|
(7,721 |
) |
|
(3,806 |
) |
||
Inventory |
|
(720 |
) |
|
(6,967 |
) |
||
Prepaid expenses and other current assets |
|
950 |
|
|
6,033 |
|
||
Accounts payable |
|
(652 |
) |
|
(974 |
) |
||
Accrued expenses and other liabilities |
|
(5,592 |
) |
|
(23,405 |
) |
||
Deferred revenue |
|
1,081 |
|
|
4,342 |
|
||
Operating lease liabilities |
|
(214 |
) |
|
(195 |
) |
||
Cash flows from operating activities |
|
32,560 |
|
|
1,300 |
|
||
Cash flows from investing activities: |
|
|
||||||
Proceeds from the sale and maturities of investments |
|
109,000 |
|
|
123,035 |
|
||
Purchases of investments |
|
(127,041 |
) |
|
(91,986 |
) |
||
Purchases of property, equipment and intangible assets |
|
(39 |
) |
|
(17 |
) |
||
Cash flows from investing activities |
|
(18,080 |
) |
|
31,032 |
|
||
Cash flows from financing activities: |
|
|
||||||
Purchase of common shares under Share Repurchase Plan |
|
(36,165 |
) |
|
(46,921 |
) |
||
Payments of principal portion of Monoplant finance lease liability |
|
(3,653 |
) |
|
(2,771 |
) |
||
Proceeds from issuance of common shares for equity awards |
|
713 |
|
|
9,288 |
|
||
Tax withholding payments related to net settlements of equity awards |
|
(14,580 |
) |
|
(8,933 |
) |
||
Cash flows from financing activities |
|
(53,685 |
) |
|
(49,337 |
) |
||
Net decrease in cash, cash equivalents and restricted cash |
|
(39,205 |
) |
|
(17,005 |
) |
||
Cash, cash equivalents and restricted cash, beginning of the period |
|
80,213 |
|
|
83,433 |
|
||
Cash, cash equivalents and restricted cash, end of the period |
$ |
41,008 |
|
$ |
66,428 |
|
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20260507497614/en/
General Investor Inquiries
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.